• A Pradalier, A Guérard des Lauriers, F Scheck, P Peraudeau, J P Lacoste, and F Cajfinger.
• Service de Médecine Interne IV, Centre Hospitalier Louis-Mourier, COLOMBES, France.
• Pathol. Biol. 1995 Nov 1; 43 (9): 806-13.

AbstractIn this randomised, double-blind, cross-over study the association of calcium carbasalate+metoclopramide was compared with oral dihydroergotamine mesilate in the treatment of migraine attacks. 155 patients suffering from migraine, with or without aura were analysed; the main efficacy criteria being the evolution of the headache intensity: disappearance of headache 2 hours after administration or incomplete improvement (severe to moderate headache reduced to slight headache). There was a significantly greater reduction in headache intensity following administration of CSC-METO (p < 0.001), the percentage of patients showing recovery or improvement two hours after administration being 64.5% with CSC-METO compared to 43.5% with DHE. A significantly more marked improvement following administration of CSC-METO was also observed for nausea, photophobia, phonophobia, use of analgesic treatment, impact on normal activities and overall assessment by the patient and physician. The frequency of undesirable events was weak and identical for both treatments.

30 keywords...

hide…